Clinical trials: Chronic Obstructive Pulmonary Disease Severe
- Condition Chronic Obstructive Pulmonary Disease Severe
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Chronic Obstructive Pulmonary Disease
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to evaluate, after 1 week of dosing, the efficacy and safety of PT003 compared with its individual components (PT001 and PT005), placebo and two active comparators to demonstrate superiority of the…
- Trial name
- NCT01085045
- Testing
- PT003 MDI, PT005 MDI, Tiotropium bromide 18 μg (Spiriva Handihaler®)
- Where
- 16 sites in United States, Australia and 1 more
- Volunteers
- 118 people
- Sponsor
- Pearl Therapeutics, Inc.
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster® in COPD
Randomized,double-blind,multicenter,multinational,parallel-group,Phase III study to demonstrate the superiority of the triple fixed combination of beclometasone + formoterol + glycopyrrolate (BDP/FF/GB) administered via…
- Trial name
- TRILOGY (NCT01917331)
- Testing
- Beclometasone/Formoterol/Glycopyrrolate, Beclometasone/Formoterol
- Where
- Hungary
- Volunteers
- 1,368 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Chronic Obstructive Pulmonary Disease
Evaluation of Efficacy on Exercise Tolerance of Symbicort (Budesonide/Formoterol) Compared to Placebo and Oxis in Patients With Severe COPD
The purpose of this study is to investigate the effect on exercise tolerance, lung function and symptoms after treatment with Symbicort, Oxis or placebo in patients with severe chronic obstructive pulmonary disease.
- Trial name
- CODEX (NCT00489853)
- Testing
- budesonide/formoterol Turbuhaler 320/9µg, formoterol Turbuhaler 9µg
- Where
- 9 sites in Germany, Switzerland
- Volunteers
- 137 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The study assessed the safety and efficacy of the fixed combination product QVA149 versus the component products QAB149 and NVA237, administered concurrently, in patients that have moderate to severe chronic obstructive pulmonary…
- Trial name
- BEACON (NCT01529632)
- Testing
- QVA149, NVA237, QAB149
- Where
- 26 sites in Austria, Denmark and 3 more
- Volunteers
- 193 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01309737
- Testing
- CP-690,550
- Where
- 94 sites in United States, Canada and 9 more
- Volunteers
- 960 people
- Sponsor
- Pfizer
Chronic Obstructive Pulmonary Disease (COPD)
The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This study will assess the efficacy and safety of QVA149 compared to tiotropium plus formoterol in patients with moderate to severe COPD.
- Trial name
- QUANTIFY (NCT01574651)
- Testing
- QVA149, Tiotropium, Formoterol
- Where
- 144 sites in Germany
- Volunteers
- 934 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
To evaluate the efficacy of CP-690,550 as compared to etanercept and the safety of CP-690,550 for treatment of moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01241591
- Testing
- CP 690,550 5 mg, CP 690,550 10 mg, Etanercept 50 mg
- Where
- 122 sites in Argentina, Austria and 24 more
- Volunteers
- 1,101 people
- Sponsor
- Pfizer
Moderate to Severe COPD
Study to Assess the Efficacy and Safety of AZD1981 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to study efficacy and safety of AZD1981 in patients with Chronic Obstructive Pulmonary Disease
- Trial name
- Columbus (NCT00690482)
- Testing
- AZD1981
- Where
- 21 sites in Bulgaria, Denmark and 3 more
- Volunteers
- 118 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.
This study will assess the efficacy, safety and tolerability of QVA149 in patients with moderate to severe airflow limitation.
- Trial name
- NCT01727141
- Testing
- QVA149, QAB149, NVA237
- Where
- 143 sites in United States, Canada and 6 more
- Volunteers
- 1,042 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Randomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With COPD.
This study is designed to assess the effect of QVA149 (110/50 ug q.d.) versus placebo on pulmonary function and average physical activity levels in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- MOVE (NCT01996319)
- Testing
- QVA149
- Where
- 30 sites in Germany
- Volunteers
- 194 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Safety/Tolerability Study With AZD1236 in Chronic Obstructive Pulmonary Disease (COPD) Patients
The primary aim of this study is to investigate the tolerability and safety of AZD 1236 compared with placebo ("inactive substance") in COPD patients by assessment of Adverse Events, vital signs and laboratory safety assessments.
- Trial name
- CERA (NCT00758459)
- Testing
- AZD1236
- Where
- 14 sites in Bulgaria, Finland and 3 more
- Volunteers
- 74 people
- Sponsor
- AstraZeneca
COPD
Study to Evaluate the Treatment Effect of PT003 on Cardiovascular Hemodynamics in Subjects With Moderate to Severe COPD
This is a randomized, double-blind, placebo-controlled, single-center, chronic-dosing (7 days), two-period, two-treatment, cross-over study to evaluate the treatment effect of PT003 compared with that of Placebo MDI on…
- Trial name
- NCT02685293
- Testing
- GFF MDI (PT003)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Pearl Therapeutics, Inc.
COPD
Crossover Study to Assess the Efficacy of PT003 With and Without a Valved Holding Chamber in Subjects With Moderate to Severe COPD
This is a Randomized, Phase III, Two-period, Open-label, Chronic-dosing (7 Days), Multi-center, Crossover Study to Assess the Efficacy of PT003 in Subjects with Moderate to Severe COPD with and without a Valved Holding Chamber.
- Trial name
- NCT02454959
- Testing
- GFF MDI (PT003) with Aerochamber, GFF MDI (PT003) without Aerochamber
- Where
- 6 sites in United States
- Volunteers
- 80 people
- Sponsor
- Pearl Therapeutics, Inc.
Chronic Obstructive Pulmonary Disease (COPD)
A Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of Aclidinium Bromide 400 μg Bid on COPD Symptoms and Sleep Quality After 3 Weeks of Treatment in Patients With Stable Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to assess the effect of aclidinium bromide compared with placebo in improving dilatation of the airways (bronchodilation), symptoms of chronic obstructive pulmonary disease (COPD), sleep quality and…
- Trial name
- NCT02153489
- Testing
- Aclidinium bromide
- Where
- 2 sites in Germany
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Graft vs Host Disease
Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant
This open-label, single-arm, Phase II multi-center study enrolled 46 participants and investigated the activity, pharmacokinetics and safety of ruxolitinib added to the subject's immunosuppressive regimen among infants, children…
- Trial name
- REACH 5 (NCT03774082)
- Testing
- INC424
- Where
- 21 sites in Brazil, Canada and 12 more
- Volunteers
- 46 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease (COPD)
Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)
This is a multi-center, randomized, double-blind, parallel group, chronic dosing, active-controlled, 28-week safety extension study of the two pivotal 24-week safety and efficacy studies (Studies PT003006 and PT003007).
- Trial name
- NCT01970878
- Testing
- GFF MDI (PT 003), GP MDI (PT001), FF MDI (PT005)
- Where
- 125 sites in United States, Australia and 1 more
- Volunteers
- 892 people
- Sponsor
- Pearl Therapeutics, Inc.
Chronic Obstructive Pulmonary Disorder
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
This is a Phase III randomized, double-blind, parallel group, multi-center, 24-week lung function study with BFF MDI (320/9.6 μg and 160/9.6 μg) compared to FF MDI 9.6 μg, BD MDI 320 μg, and open-label Symbicort® TBH (200/6 μg)…
- Trial name
- telos (NCT02766608)
- Testing
- BFF MDI 320/9.6 μg, BFF MDI 160/9.6 μg, FF MDI 9.6 μg
- Where
- 259 sites in United States, Canada and 6 more
- Volunteers
- 2,389 people
- Sponsor
- Pearl Therapeutics, Inc.
COPD
Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)
This is a randomized, double-blind, multi-center, parallel-group study to assess the efficacy and safety of PT010 relative to PT003 and PT009 on COPD exacerbations subjects with moderate to very severe COPD.
- Trial name
- NCT02465567
- Testing
- BGF MDI 320/14.4/9.6 μg, GFF MDI 14.4/9.6 μg, BGF MDI 160/14.4/9.6 μg
- Where
- 741 sites in United States, Argentina and 24 more
- Volunteers
- 8,588 people
- Sponsor
- Pearl Therapeutics, Inc.
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Aclidinium Bromide 400 µg BID (Twice a Day)Compared to Placebo in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The aim of the present study is to evaluate the effect of aclidinium bromide 400 μg twice a day (BID) administered twice a day versus placebo on exercise endurance and on hyperinflation and dyspnoea at rest and during exercise…
- Trial name
- NCT01471171
- Testing
- Aclidinium Bromide
- Where
- 14 sites in Germany, Spain and 1 more
- Volunteers
- 112 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)
Nemiralisib is being developed as an anti-inflammatory drug for the treatment of inflammatory airways disease. This study is designed to assess the dose response, efficacy, safety, and pharmacokinetics of nemiralisib across a…
- Trial name
- NCT03345407
- Testing
- Nemiralisib ELLIPTA 50 µg, Nemiralisib ELLIPTA 100 µg, Nemiralisib ELLIPTA 250 µg
- Where
- 161 sites in United States, Argentina and 14 more
- Volunteers
- 943 people
- Sponsor
- GlaxoSmithKline